# Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients

> **NCT03376503** · PHASE1 · COMPLETED · sponsor: **Nanogen Pharmaceutical Biotechnology Joint Stock Company** · enrollment: 24 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT03376503
- **Lead sponsor:** Nanogen Pharmaceutical Biotechnology Joint Stock Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-25
- **Primary completion:** 2017-10-09
- **Final completion:** 2017-11-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03376503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03376503, "Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03376503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*